We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ghassan Abou-Alfa

Ghassan K. Abou-Alfa MD, MBA

Attending Physician, Memorial Sloan Kettering Cancer Center; Professor, Weill Medical College at Cornell University, New York, New York

Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. He completed his residency and fellowship at Yale University, and later joined the Yale faculty. He received an MBA from Columbia University. Professor Abou-Alfa served as Chair of the National Cancer Institute (NCI) Hepatobiliary Task Force for two consecutive terms; and is member of the NCI AIDS Malignancy Consortium Steering Committee. Professor Abou-Alfa is the President for the International Society of Gastrointestinal Oncology is a trustee of the American University of Beirut; and serves on the American Society of Oncology (ASCO) International Affairs Committee.

Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies with extensive expertise in hepatocellular carcinoma (HCC), cholangiocarcinoma, gallbladder cancer, and fibrolamellar carcinoma (FLC). Professor Abou-Alfa’s research focuses on advancing checkpoint inhibitors and small biological molecules into standard cancer therapies, determining the right CAR-T antigens for HCC and FLC, and analyzing international patient biographies to help determine the appropriate therapy. Under the auspices of the MSK International Center, Professor Abou-Alfa, helped establish, maintain, and flourish a strong global relationship with different institutions worldwide.

Disclosures

Dr. Abou-Alfa reports the following:
  • Research support from ActaBiologica, Agios, Astra Zeneca, Bayer, Beigene, Berry Genomics, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Mabvax, Polaris, Puma, QED, Roche, and Sillajen.
  • Consulting for Agios, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Celgene, CytomX, Debio, Eisai, Eli Lilly, Flatiron, Genentech, Gilead, Incyte, Ipsen, LAM, Loxo, Merck, MINA, QED, Redhill, Roche, Silenseed, Sillajen, Sobi, Therabionics, Twoxar, Vector, and Yiviva.